Drugs / OBI-3424
OBI-3424
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04315324 | Feb 2021 → Aug 2026 overdue | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06239155 | Sep 2019 → Nov 2025 overdue | hepatocellular carcinoma | Ascentawits Pharmaceuticals, Ltd | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03592264 | Jul 2018 → Feb 2024 | pancreatic adenocarcinoma | OBI Pharma, Inc | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07310173 | Jan 2026 → Oct 2027 expected | hepatocellular carcinoma | Zhejiang Hisun Pharmaceutical Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBI-3424 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03592264 ↗ |
| Known as | AST-3424 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06239155 ↗ |
| Known as | TH-3424 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297474 ↗ |
| Modality | Small molecule | “OBI-3424 is an investigational small-molecule prodrug.” PMID 42390142 ↗ Jul 2026 |
| Route | Intravenous | “OBI-3424 administered intravenously” PMID 37173365 ↗ May 2023 |